HOME  | CONTACT  | PATIENT LOGIN  | CLINIC LOGIN  | FAQ
  • PATIENTS &
    HEALTHY VOLUNTEERS
  • INVESTIGATORS
  • CROS / SPONSORS
  • CAREERS
  • TRIAL ALERTS

TRIALS SEARCH
      
  • HEALTH NEWS

  • RSS FEEDS

  • ABOUT TRIALS

  • LINK TO US


View Clinical Trial (Medical Research Study)


Peer-driven Intervention to Seek, Test & Treat Heterosexuals at High Risk for HIV

Signup
Browse Studies

City:   New York
State:   New York
Zip Code:   10003
Conditions:   HIV/AIDS - Vulnerable Populations - Heterosexuals at High Risk
Purpose:   Approximately 21% of HIV infections in the U.S. are undiagnosed, but only about 40% of all adults have been tested. Thus, late diagnosis of HIV is common, and, furthermore, treatment delays and disruptions are widespread. Heterosexuals at high risk (HHR) are significantly less likely to test for HIV, are more likely to be diagnosed with HIV late, and experience serious barriers to entering care compared to other groups. The investigators research team has studied HHR in New York City (NYC) as part of the CDC's National HIV Behavioral Surveillance (NHBS) studies. The investigators found an HIV prevalence rate of 7.4% among HHR in NYC, and only 6% of these infections had been previously diagnosed. Further, in central Brooklyn, 10% were newly diagnosed with HIV. The proposed study will use NHBS methodology to target HHR in central Brooklyn. The primary goal of the proposed study is to evaluate the efficacy of a peer-driven intervention (PDI) to seek, test, treat and retain HHR. The investigators will also compare the effectiveness of two sampling methods to reach HHR: Respondent-driven sampling (a peer-based approach) versus venue-based sampling (a location-based approach). The two main study hypotheses are: (H1): Participants recruited by respondent-driven sampling (RDS) will be more likely to test positive for HIV compared to those recruited via venue-based sampling H2): Participants in the "Test and Treat: phase of the peer-driven intervention (all of whom will be HIV-infected) will show a shorter time to an HIV clinical appointment, a shorter time to starting HIV medication (when medically indicated), higher rates of viral load suppression, and higher rates of retention in care compared to those in the control arm.
Study Summary:   Approximately 21% of HIV infections in the U.S. are undiagnosed, but only about 40% of all adults have been tested. Thus, late diagnosis of HIV is common, and, furthermore, treatment delays and disruptions are widespread. Heterosexuals at high risk (HHR) are significantly less likely to test for HIV, are more likely to be diagnosed with HIV late, and experience serious barriers to entering care compared to other groups. Our research team has studied HHR in New York City (NYC) as part of the CDC's National HIV Behavioral Surveillance (NHBS) studies. The investigators found an HIV prevalence rate of 7.4% among HHR in NYC, and only 6% of these infections had been previously diagnosed. Further, in central Brooklyn, 10% were newly diagnosed with HIV. The proposed study will use NHBS methodology to target HHR. Reduced rates of HIV testing and treatment among HHR are due to structural (e.g., poor access), social (e.g., peer norms), and individual-level (e.g., low perceived risk) barriers. Thus active recruitment approaches modeled after NHBS are needed to overcome structural barriers, and peer-delivered interventions effectively reduce individual and social barriers to testing and treatment. The primary goal of the proposed study is to evaluate the efficacy of a multi-level enhanced peer-driven intervention (PDI) to seek, test, treat and retain HHR. The enhanced PDI is tailored specifically for HHR and includes computerized, navigation, and peer-delivered components to enhance future sustainability. The design of the intervention is guided by the Theories of Triadic Influence and Normative Regulation. Similar to NHBS, the enhanced PDI will use respondent-driven sampling (RDS). NHBS protocols use both venue-based sampling (VBS) and RDS for reaching populations at high risk. However, VBS and RDS have not yet been directly compared in terms of their yield of undiagnosed HIV infections. Thus the specific aims of this five-year proposed study are to: (1) compare the yield and efficiency of RDS and VBS to identify undiagnosed HIV infection among HHR; (2) measure the efficacy of an enhanced PDI compared to a control in terms of time to HIV care and HAART initiation, viral load suppression, and retention among those newly-diagnosed; (3) examine whether the effects of the PDI on HIV health/treatment outcomes are mediated by changes in individual (e.g., perceived risk), social (e.g., peer norms), and structural influences (e.g., enhanced access), and/or whether other factors (e.g., substance use) moderate its effects; and (4) to project the costs and cost-effectiveness of RDS vs. VBS and PDI. The investigators will conduct the enhanced PDI (N=3000) in central Brooklyn, a location hyperendemic for HIV and where HHR experience poor access to testing and treatment. Simultaneously, VBS (N=400) will be undertaken in central Brooklyn. The proposed study complements local and national HIV prevention initiatives and is designed to contribute an efficient, innovative, and sustainable multi-level recruitment approach and intervention to the HIV prevention portfolio. The vast majority of HHR are African-American or Latino; therefore the proposed study may also impact racial/ethnic disparities in HIV/AIDS. The study's main hypotheses are as follows: (H1): Compared with venue-based sampling (VBS), and controlling for potential differences on key sociodemographic characteristics across the samples, participants recruited by respondent-driven sampling (RDS) will be more likely to test positive for HIV for the first time. H2): Participants in the Test and Treat Phase of the BCAP PDI's intervention arm (all of whom will be HIV-infected) will evidence a shorter time to an HIV clinical appointment, a shorter time to initiating HAART (when medically indicated), higher rates of viral load suppression, and higher rates of retention in care compared to those in the control arm.
Criteria:   Inclusion Criteria: - aged 18-50 years - sexually active (vaginal, anal) with at least 1 opposite sex partner within the previous year - reside in the central Brooklyn HRA defined in the Development Phase - African-American or Latino/Hispanic race/ethnicity - comprehend English or Spanish - HIV negative or unknown HIV status - not tested for HIV within the past 12 months - willing to provide locator information - willing to try to recruit peers - not actively psychotic based on valid screening instrument - not a participant in the two past NHBS studies with HHR (called HET1/HET2); not enrolled already in VBS or PDI/RDS in this study - willing to be randomly assigned to intervention arm (initial seeds only for PDI component)
NCT ID:   NCT01607541
Primary Contact:   Principal Investigator
Marya Gwadz, PhD
New York University

Marya Gwadz, Ph.D.
Phone: 212-992-7147
Email: mg2890@nyu.edu
Backup Contact:   Email: amanda.ritchie@nyu.edu
Amanda Ritchie, MAA
Phone: 212-992-7186
Location Contact:   New York, New York 10003
United States



There is no listed contact information for this specific location.

Site Status: Recruiting

Data Source:   ClinicalTrials.gov
Date Processed:   May 20, 2013
Modifications to this listing:   Only selected fields are shown, please use the link below to view all information about this clinical trial.
Click to view Full Listing


If you would like to be contacted by the clinical trial representative please enter your contact information, then click "I Am Interested In This Study"
First Name:  
Last Name:  
Email Address:  
Confirm Email:    
Daytime Phone (eg. 555-555-5555):  
City:  
State:
Zip Code:    
Best Time to Call:  
Questions/Comments:  
  • NEARBY STUDIES

Within 25 Miles

Post-Herpetic Neuralgia (PHN) (Post-Shingles Pain) - New York NY (Clinical Trial 3231)

Major Depressive Disorder - New York NY

Depression - New York NY

Social Anxiety Disorder - New York NY

Depression - New York NY

Bipolar Depression - New York NY

Gout - New York NY

Crohn's Disease - Great Neck NY

Diabetic Foot Pain - New York NY

Generalized Anxiety Disorder - New York NY

Depression - New York NY

Irritable Bowel Syndrome with Diarrhea (IBS-D) - Great Neck NY

Irritable Bowel Syndrome with Diarrhea (IBS-D) - Great Neck NY

Crohn's Disease - Great Neck NY

Arthritis - Edison NJ

Arthritis - Hartsdale NY

Gout - New York NY

Dry Eye - Wantagh NY

Irritable Bowel Syndrome (with diarrhea) - New York NY

Lower Back Pain - New York NY

Depression - New York NY

Postherpetic Neuralgia (Post-shingles pain) - New York NY

Chronic Low Back Pain - Great Neck NY

Multiple Myeloma, Mantle Cell Lymphoma, Diffuse Large B Cell Lymphoma - Hackensack NJ

Arthritis - Roslyn NY

Treatment Resistant Depression - New York NY

Irritable Bowel Syndrome with Diarrhea (IBS-D) - New York NY

Low Back Pain and Constipation - New York NY

Low Back Pain and Constipation - Staten Island NY

Low Back Pain and Constipation - Great Neck NY

Low Back Pain and Constipation - Cedarhurst NY

Anti-Depressant Induced Sexual Dysfunction - New York NY

Anti-Depressant Induced Sexual Dysfunction - Staten Island NY

Anti-Depressant Induced Sexual Dysfunction - Staten Island NY

Irritable Bowel Syndrome (with diarrhea) - Kew Gardens NY

Irritable Bowel Syndrome (with diarrhea) - Hartsdale NY

Acne - New York NY

Asthma - Brooklyn, NY

Uncontrolled Angina (Adult Stem Cell Research) - Newark NJ

Uncontrolled Angina (Adult Stem Cell Research) - New York NY

Brain Tumor (Glioblastoma) - Hackensack NJ

Brain Tumor (Glioblastoma) - West Harrison NY

Eating Disorder - Jamaica NY

COPD (Emphysema and Chronic Bronchitis) - Summit NJ

COPD (Emphysema and Chronic Bronchitis) - Great Neck NY1

COPD (Emphysema and Chronic Bronchitis) - Brooklyn NY 2

COPD (Emphysema and Chronic Bronchitis) - Great Neck NY2

COPD (Emphysema and Chronic Bronchitis) - New York NY

Depression - New York NY

Acne Vulgaris - Bronx NY

Within 50 Miles

Prostate Cancer - Goshen NY

Vaginal Dryness - Plainsboro NJ

Pediatric Depression - Mount Kisco NY

Irritable Bowel Syndrome (with diarrhea) - Norwalk CT

Irritable Bowel Syndrome (with diarrhea) - Stamford CT

Chronic Low Back Pain - Stamford CT

Non-Hodgkin's Lymphoma - Mount Kisco NY

Prostate Cancer - Mount Kisco NY

Breast Cancer - Mount Kisco NY

Myelodysplastic Syndrome - Mount Kisco NY

Within 100 Miles

Prostate Cancer - Bethlehem PA

Crohn's Disease - Hamden CT

Crohn's Disease - Poughkeepsie NY

Contraceptive Gel - Philadelphia PA

Bipolar Disorder - Media PA

Endometriosis - Philadelphia PA

Bipolar Disorder - Media PA

Asthma - Danbury CT

Schizophrenia - Norristown PA

Emphysema/COPD (Chronic Obstructive Pulmonary Disease) - Philadelphia PA

Obsessive Compulsive Disorder (OCD) - Norristown PA

HPV - Philadelphia PA

Irritable Bowel Syndrome with Diarrhea (IBS-D) - Waterbury CT

Endometriosis - Danbury CT

Arthritis - Toms River NJ

Arthritis - Norristown PA

Bipolar Disorder - Cherry Hill NJ

Depression - Cherry Hill NJ

Gout - Jenkintown PA

Dry Eye - Danbury CT

Excessive Daytime Sleepiness with Narcolepsy - Philadelphia PA

Arthritis - Bristol CT

Restless Legs Syndrome (RLS) - Philadelphia PA

Restless Legs Syndrome (RLS) - Toms River NJ

Dry Eye - Philadelphia PA

Irritable Bowel Syndrome (with diarrhea) - New Windsor NY

Irritable Bowel Syndrome (with diarrhea) - Poughkeepsie NY

Irritable Bowel Syndrome (with diarrhea) - Philadelphia PA

Irritable Bowel Syndrome (with diarrhea) - Lansdale PA

Postherpetic Neuralgia (Post-shingles pain) - Toms River NJ

Arthritis - Sicklerville NJ

Multiple Sclerosis - Philadelphia PA

Asthma (Ages 18-65) - Chester PA

Asthma (Ages 18-65) - Collegeville PA

Gout - Milford CT

Low Back Pain and Constipation - Waterbury CT

Low Back Pain and Constipation - Toms River NJ

Low Back Pain and Constipation - New Windsor NY

Low Back Pain and Constipation - Jenkintown PA

Low Back Pain and Constipation - Levittown PA

Low Back Pain and Constipation - Philadelphia PA

Low Back Pain and Constipation - Phoenixville PA

Anti-Depressant Induced Sexual Dysfunction - Willingboro NJ

Anti-Depressant Induced Sexual Dysfunction - Toms River NJ

Anti-Depressant Induced Sexual Dysfunction - Allentown PA

Anti-Depressant Induced Sexual Dysfunction - Philadelphia PA

Irritable Bowel Syndrome (with diarrhea) - Voorhees NJ

Irritable Bowel Syndrome (with diarrhea) - Jenkintown PA

Obsessive Compulsive Disorder (OCD) - Norristown PA

Obsessive Compulsive Disorder (OCD) - New Haven CT

Arthritis - Hamden CT

Uncontrolled Angina (Adult Stem Cell Research) - Haddon Heights NJ

Uncontrolled Angina (Adult Stem Cell Research) - Philadelphia PA

Asthma (Ages 18-65) - Feasterville PA

Brain Tumor (Glioblastoma) - Philadelphia PA

Arthritis - Feasterville Trevose PA

Anxiety - Cherry Hill NJ

COPD (Emphysema and Chronic Bronchitis) - Marlton NJ

COPD (Emphysema and Chronic Bronchitis) - Phoenixville PA

 
Clinical Connections Home | Investigators | CROs / Sponsors | Clinical Trials Notification | Search Clinical Trials | About Clinical Trials | Links | Terms And Conditions | Sitemap | Suggestions / Feedback
© 1998-2013 | All trademarks are property of their legal owners. | All Rights Reserved

ClinicalConnection.com is a resource that provides individuals with information regarding clinical trials that are being conducted worldwide.

ClinicalConnection.com does not conduct these clinical trials nor endorse them. Please consult your doctor or physician before participating.